COVINGTON, Ky. — Bexion Pharmaceuticals Inc. announced Tuesday that the company has assembled a clinical advisory board to be comprised of key opinion leaders in various oncology specialties. Their purpose is to review and provide expert guidance on the overall clinical development plan, including designs and implementation of proposed clinical studies.
Members include:
Manmeet Ahluwalia, MD, FACP is the Dean and Diane Miller Family Endowed Chair in Neuro-Oncology in the Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center (BBTC) at the Cleveland Clinic Taussig Cancer Institute, where he subspecializes in treatment of patients with brain tumors and brain metastases. He is currently leading several clinical trials involving immune therapy and new targeted therapies as well as treatments targeting tumor blood vessels (angiogenesis) and cancer stem cells. Dr. Ahluwalia received his MD degree from the Maulana Azad Medical College, University of Delhi. He completed his residency at Fairview General Hospital and fellowship training at the Roswell Park Cancer Institute.
Timothy P. Cripe, MD, PhD, FAAP, is chief of the Division of Hematology and Oncology at Nationwide Children’s Hospital, a Gordon Teter Endowed Chair in Pediatric Cancer at Nationwide Children’s Hospital and a professor of pediatrics at The Ohio State University. Dr. Cripe received his undergraduate degree in Biochemistry from Princeton University and his M.D. and Ph.D. in Genetics from the University of Iowa. He completed his pediatric residency training at the University of Iowa Children’s Hospital and his subspecialty fellowship training in pediatric hematology/oncology from Dana-Farber Cancer Institute/Children’s Hospital, Boston and the University of Colorado/Children’s Hospital, Denver. He was on faculty at the University of Wisconsin-Madison and Cincinnati Children’s Hospital prior to coming to Nationwide Children’s.
Richard C. Curry III, MD, cares for patients who are navigating through the life-altering journey of brain cancer. His patients and their families can immediately feel comfortable and at ease as he is dedicated to working with them through such a difficult process. Dr. Curry served as Chief Resident for the University of Cincinnati’s Department of Neurology. He received additional training in Neuro-Oncology at Memorial Sloan-Kettering Cancer Center in New York City. Additionally, he has volunteered for several global organizations, treating neurological diseases and setting up medical clinics in local villages.
Olivier Rixe, MD, PhD, moved to New Mexico in 2014 when he was recruited to serve as the Cancer Center Associate Director for Clinical Research and the Director of the Experimental Therapeutics Unit at the University of New Mexico Cancer Center. While there, he was named the Dana Wood Endowed Chair in Cancer Therapeutics and Early Phase Clinical Research. He recently joined the Santa Fe Cancer Center where he is leading the Experimental Therapeutics Program. He previously worked at the Gustave-Roussy Institute, Pierre and Marie Curie/Sorbonne University, the National Cancer Institute, and the University of Cincinnati Cancer Institute. He has published more than 140 papers in clinical and translational oncology research. His most recent passion is a larger vision of the oncology practice, searching for a better holistic care and a fusion of scientific evidences with spiritual healing, from preventive medicine to treatment of advanced cancer care.
“We are very honored and gratified Bexion has attracted this group of world-renowned oncology investigators to advise us on advancing Bexion’s lead oncology candidate, BXQ-350”, stated Dr. Ray Takigiku, founder and CEO of Bexion. “We are looking forward to the insights and expertise to be brought by Drs. Ahluwalia, Cripe, Curry, and Rixe as founding members of our CAB.”
Add Comment